Source: Xconomy

RA Capital: Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies

Drugs designed to precisely target cancers with specific genetic signatures have changed the course of disease for many patients. But for the majority, such drugs either don't work because of innate resistance or they eventually stop working once the cancer develops new mutations that hamper their effectiveness. Kinnate Biopharma, one of the biotechs working to [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Peter Kolchinsky's photo - Managing Partner of RA Capital

Managing Partner

Peter Kolchinsky

CEO Approval Rating

68/100

RA Capital Management is a venture capital firm that invests in healthcare and life-sciences companies. Read more